Preclinical data from Ascletis Pharma show ASC36 35 FDC, a fixed-dose combination of the GLP-1 agonist Eloralintide and the dual GIP/GLP-1 agonist Tirzepatide, achieved superior weight loss versus co-administration of the same two agents. The results are set for oral presentation at the 62nd EASD…
Ascletis Pharma has announced that ASC36 35 FDC , its investigational fixed-dose combination of the GLP-1 receptor agonist Eloralintide and the dual GIP and GLP-1 receptor agonist Tirzepatide , achieved superior weight loss compared with co-administration of the same two agents in preclinical studies. The data are scheduled to be presented as an oral discussion at the 62nd EASD Annual Meeting, the annual conference of the European Association for the Study of Diabetes.
The head-to-head claim is the new element. It states that a single fixed-dose product containing two incretin-based peptides produced a better weight loss result than giving the identical two peptides at the same time from separate products. Ascletis positions ASC36 35 FDC as a potentially more effective treatment option for obesity and related metabolic conditions, with the fixed-dose format designed to enhance weight loss efficacy while simplifying dosing for patients.
If the preclinical result translates to humans, it would suggest that how combination peptides are formulated, not just which peptides are chosen, can shape the weight loss response. That is a direct question for peptide researchers, and the EASD presentation is the venue where the underlying data will first be examined.
The product is designated ASC36 35 and contains two active agents: Eloralintide and Tirzepatide. Eloralintide is a GLP-1 receptor agonist. Tirzepatide is a single peptide that activates both the GIP and the GLP-1 receptors. The fixed-dose combination brings the two into one product rather than leaving patients or prescribers to manage two separate injections.
The stated rationale has two parts. The efficacy claim is that the combination enhances weight loss beyond what co-administration delivers. The convenience claim is that a single fixed-dose product simplifies dosing. Both claims are common in fixed-dose combination development, but the efficacy claim in this case rests on a direct comparison against co-administration rather than against placebo or single agents.
The announcement is thin on numbers. No quantitative weight-loss figures were disclosed. The company did not report doses, dose ratios, sample sizes, or study duration, and it did not say which preclinical model or models were used. The disclosed result is directional: ASC36 35 FDC demonstrated superior weight loss versus co-administration of Eloralintide and Tirzepatide, and the data will be presented in an oral discussion at the 62nd EASD Annual Meeting.
The study, as described, is a direct comparative experiment: ASC36 35 FDC versus co-administration of Eloralintide and Tirzepatide, with weight loss as the endpoint and a superiority claim as the outcome. Population, sample size, and duration have not been disclosed, so the design details will not be fully knowable until the oral discussion at the 62nd EASD Annual Meeting.
The design is notable for what it isolates. Comparing the fixed-dose combination against co-administration of the same two molecules separates the formulation from the pharmacology. A comparison against placebo or against either single agent would show that the combination works, but it would not show whether co-formulation changes the outcome. The head-to-head against co-administration asks a sharper question: does putting two peptides in one product do something that giving them together from separate products does not?
Preclinical weight loss studies are an early filter for obesity candidates, and they have limits. Animal models can show the direction and relative size of an effect, but they do not predict human efficacy, tolerability, or dose selection with certainty. The design also cannot address adherence, the main clinical argument for a fixed-dose product. At most, this study establishes a preclinical efficacy difference attributable to co-formulation. It does not establish human safety, human pharmacokinetics, or the size of the effect.
The biology runs through the incretin system . GLP-1 receptor agonism stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on central circuits to reduce appetite. Tirzepatide layers GIP receptor agonism onto GLP-1 activity within a single molecule. GIP, long viewed mainly as a glucose-dependent insulin secretagogue, is now understood to act on adipose tissue and central feeding circuits in ways that may complement GLP-1 signaling.
Eloralintide's mechanism overlaps with the GLP-1 component of tirzepatide. The combination therefore concentrates GLP-1 activity while adding tirzepatide's GIP activity. Whether that arrangement adds efficacy over tirzepatide alone, or over co-administration, is an empirical question that the disclosed data do not answer. The head-to-head result, if confirmed, would point to the formulation itself as the source of the difference.
Co-formulating two peptides introduces variables that separate administration does not. The two molecules must have compatible solubility, stability, and release profiles in a single vehicle, and the formulation can alter absorption kinetics, exposure peaks, and the timing of each peptide's action. One plausible explanation for a formulation effect is that co-formulation coordinates the pharmacokinetic relationship between the two peptides in a way that separate injections do not. Another is altered absorption at the injection site. Neither can be tested with the information disclosed so far, but the head-to-head design is the correct way to ask the question.
Tirzepatide's clinical footprint is large. Peptide Atlas holds 251 registered clinical trials for tirzepatide on file. The phase breakdown among registered trials is 5 in Phase 2, 2 in Phase 4, and 1 in Phase 3, with 10 trials currently listed as recruiting. The mix shows a molecule being tested well beyond its original metabolic indications, and the ASC36 35 program builds on that base.
The recruiting trials illustrate the range:
The literature base is similarly active. Peptide Atlas indexes 188 PubMed papers on tirzepatide. Recent items include a multicenter propensity-matched real-world study of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease Hepatol Int, 2026-07-03 ; a case report of starvation-type euglycemic ketoacidosis after unsupervised tirzepatide use in a non-obese, non-diabetic woman Am J Case Rep, 2026-07-01 ; a review of tirzepatide as a multi-organ integrator in metabolic diseases Endocrine, 2026-07-01 ; a retrospective cohort showing improved metabolic outcomes in people with type 1 diabetes and overweight or obesity Diabetes Obes Metab, 2026-07-01 ; and a multicenter real-world comparison of tirzepatide and semaglutide for obesity Mayo Clin Proc, 2026-06-30 .
On the supply side, Peptide Atlas has 4 third-party lab purity tests on file for tirzepatide, with the highest observed purity at 99.864% . That figure matters for the ASC36 35 program because a fixed-dose combination holds two peptides in a defined ratio, and the purity of each starting peptide constrains what the finished product can deliver. The tirzepatide reference page is at https://peptideatlas.co/peptides/tirzepatide.
For researchers, the comparison opens a design question that combination programs rarely test directly. Most combination development compares a combination against its individual parts. The ASC36 35 program, as disclosed, compares the combination against co-administration of those parts, which treats the formulation as a variable in its own right. If the result holds up at the 62nd EASD Annual Meeting, it would give combination peptide developers a reason to run the same comparison in their own programs and to design pharmacokinetic studies that explain any formulation effect.
For clinicians, the payoff would come only after human trials. A fixed-dose product that matched co-administration would already simplify treatment. One that improved weight loss would do more. But the distance from a directional preclinical claim to a prescribing decision is long. Clinicians will need human efficacy and tolerability data, plus comparative data against the single agents already on the market, before this product changes practice.
For the peptide supply chain, the announcement points to the technical demands of co-formulating two peptides. Fixed-dose peptide products must keep both molecules stable and compatible through manufacturing, storage, and administration, and each batch must hold a defined ratio of the two actives. The 4 third-party purity tests on file for tirzepatide, with the highest observed purity at 99.864%, show the standard that reference materials are held to; a co-formulated product raises that standard across two peptides and their interaction in a single dosage form.
The evidence base for the superiority claim is a company announcement of preclinical results. There are no human efficacy data and no human safety data. There are no disclosed weight-loss figures, doses, dose ratios, sample sizes, or study duration. The results have not yet been presented at the 62nd EASD Annual Meeting and have not been peer-reviewed in a published venue. The announcement is company-generated and has not been independently verified.
The open questions are concrete. What quantitative weight loss difference was observed in the preclinical comparison? In which preclinical models, and at what doses or dose ratios, was ASC36 35 FDC compared with Eloralintide plus Tirzepatide co-administration? Are there any disclosed data on tolerability, pharmacokinetics, or formulation characteristics of the fixed-dose combination? And on what specific date and within which session of the 62nd EASD Annual Meeting will the oral discussion take place?
The meeting presentation is the first checkpoint, because an oral discussion at EASD normally comes with the underlying abstract, which would disclose at minimum the model, the doses, and the numerical outcomes. A peer-reviewed publication would be the second checkpoint. Human trials would be the third. Only those trials can show whether a formulation effect seen in preclinical models translates into a clinical weight loss difference. Until then, the claim stands as a directional preclinical result from the company that develops the product.
Peptides referenced: Semaglutide, Tirzepatide, Glucagon, Eloralintide, GLP-1.
Related reading: Researchers link weight loss drugs to higher hair loss risk, Slight Hair Loss Correlation Found With Slimming Drugs by Researchers, AI-Powered PeptiVerse Could Accelerate Peptide Drug Discovery, AI Platform PeptiVerse Aims to Accelerate Peptide Drug Discovery.